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ABSTRACT: Two series of naphthoquinone and anthraquinone derivatives
decorated with an aromatic/heteroaromatic chain have been synthesized and
evaluated as potential promiscuous agents capable of targeting different factors
playing a key role in Alzheimer’s disease (AD) pathogenesis. On the basis of the in
vitro biological profiling, most of them exhibited a significant ability to inhibit
amyloid aggregation, PHF6 tau sequence aggregation, acetylcholinesterase (AChE),
and monoamine oxidase (MAO) B. In particular, naphthoquinone 2 resulted as one
of the best performing multitarget-directed ligand (MTDL) experiencing a high
potency profile in inhibiting β-amyloid (Aβ40) aggregation (IC50 = 3.2 μM), PHF6
tau fragment (91% at 10 μM), AChE enzyme (IC50 = 9.2 μM) jointly with a
remarkable inhibitory activity against MAO B (IC50 = 7.7 nM). Molecular modeling
studies explained the structure−activity relationship (SAR) around the binding
modes of representative compound 2 in complex with hMAO B and hAChE
enzymes, revealing inhibitor/protein key contacts and the likely molecular rationale for enzyme selectivity. Compound 2 was also
demonstrated to be a strong inhibitor of Aβ42 aggregation, with potency comparable to quercetin. Accordingly, atomic force
microscopy (AFM) revealed that the most promising naphthoquinones 2 and 5 and anthraquinones 11 and 12 were able to impair
Aβ42 fibrillation, deconstructing the morphologies of its fibrillar aggregates. Moreover, the same compounds exerted a moderate
neuroprotective effect against Aβ42 toxicity in primary cultures of cerebellar granule cells. Therefore, our findings demonstrate that
these molecules may represent valuable chemotypes toward the development of promising candidates for AD therapy.
KEYWORDS: Naphthoquinone and anthraquinone derivatives, multitarget-directed ligands (MTDLs),
Aβ and Tau aggregation inhibition, AChE and BChE inhibition, MAO inhibition
1. INTRODUCTION
Alzheimer’s disease (AD) is a progressive neurodegenerative
disorder, mainly characterized by the loss of function and
death of neurons in different areas of the brain. In spite of the
high clinical and social impact owing to its global prevalence as
the most common form of dementia, AD etiology still has to
be clearly understood. Several factors concur to AD onset and
progression, thus playing a pivotal role in the disease
pathogenesis. The dysfunction of the basal acetylcholine
(ACh) forebrain signaling,1 deposits of β-amyloid (Aβ)2 and
tau-mediated neurofibrillary tangles (NFTs),3 and neuro-
inflammation are the major hallmarks of AD. Soluble Aβ
oligomers in concert with hyperphosphorylated tau serve as the
main pathogenic contributors of neurodegeneration in AD,
acting in a synergistic fashion to cause cell death and
neurotransmitter deficits.4,5 Also oxidative stress and free
radical formation,6 metal dyshomeostasis,7 and neuroinflam-
matory processes8 are pathological components of the disease.
The range of targets in AD is increasing, and for the most part,
enzymes have been recognized as crucial contributors to AD
onset and progression.9 Consequently, a number of molecules
have entered clinical phase study with their targets, such as
BACE1, phosphodiesterase, phospholipase A2, MAPK, and
SIRT1, as examples (clinicaltrials.gov).
Bulk of evidence supports the AD multifactorial nature as a
result of an intricate network of neurochemical factors that
need to be simultaneously modulated to strive for a better
disease outcome. In fact, the marketed anti-Alzheimer drugs,
namely, the acetylcholinesterase (AChE) inhibitors and the
NMDA receptor antagonist memantine, are regarded as merely
symptomatic, since they work against a single target,
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respectively modulating the cholinergic or glutamatergic
function.10 This scenario has drawn greater attention on the
multitarget-directed ligands (MTDL) strategy as these
molecules may exhibit significant potential on the road to
therapeutics for AD.5,11−13
In this regard, the literature contains many examples of
naphthoquinone and anthraquinone compounds from natural
sources or synthetic as endowed with promising properties
against diverse AD targets. Successfully, hybrid- and fragment-
based drug design strategies allowed the yield of multifunc-
tional molecules, also based on naphthoquinone14−16 and
anthraquinone15,17,18 scaffolds which elicited antioxidant
activity, AChE inhibition, BACE inhibition, inhibition of Aβ,
and tau aggregation.
Previously we investigated a library of thioxanthen-9-one,
xanthen-9-one, naphthoquinone (I−VIII) and anthraquinone
derivatives (IX−XIV) decorated with a basic side chain
(especially quinolizidinylalkyl chains), which displayed a
multitarget behavior by inhibiting both AChE and BChE,
and the spontaneous aggregation of β-amyloid with similar
potencies16 (Figure 1). Naphthoquinones were dual AChE-
preferring inhibitors (IC50 = 0.011−5.8 μM), while anthraqui-
nones were equipotent toward both enzymes in the low
micromolar range. On the contrary the tricyclic anthraquinone
system was more suited to promoting the inhibition of Aβ
aggregation (mean IC50 ∼ 8 μM) than smaller naphthoqui-
nones, which were generally endowed with less efficacy.
2. RESULTS AND DISCUSSION
2.1. Design. This report details our investigations to probe
new additional substitutions on the naphthoquinone and
anthraquinone scaffolds that have been tethered to an aromatic
or heteroaromatic ring through a polymethylene chain, with a
view to gaining a better understanding of their potential
multitarget (promiscuity) profiles for AD (Figure 2). These
novel hydrophobic features have been included with the aim of
favoring suited hydrophobic interactions with a sequence of
aromatic amino acids (H14QKLVFF20) of Aβ, which plays an
important role in the initial phases of molecular recognition
and structural transition and leads to Aβ aggregation in soluble
oligomers and fibrillary species.14,19,20 AChE continues to be a
crucial target for AD therapy because of its noncholinergic
functions as demonstrated by its chaperone role in β-amyloid
Figure 1. First series of the naphthoquinone and anthraquinone derivatives, bearing a dialkylaminoalkyl or a quinolizidinylalkyl chain, as multitarget
agents inhibiting cholinesterases and β-amyloid aggregation: NQ = naphthoquinone; AQ = anthraquinone.
Figure 2. Structures of the investigated naphthoquinone and anthraquinone derivatives 1−14 as MTDLs for AD.
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toxicity,21 thus promoting the multitarget approach in order to
hit at least Aβ aggregation and AChE activity.22 Besides AChE,
BChE is another target of interest in the search for anti-
Alzheimer drugs, as this enzyme exhibits a compensatory effect
in response to a greatly decreased AChE activity in the central
nervous system (CNS) during AD progression.23 Additionally,
excessive monoamine oxidase (MAO) activity contributes to
neurodegeneration in AD, inducing Aβ fibrillogenesis,24
imbalance of cholinergic, glutamatergic, and noradrenergic
functions,25 and oxidative stress.26 Accordingly, the design of
MAO inhibitors, or even better multipotent MAO and ChEs
inhibitors, rapidly increased with a view to improving cognitive
deficits and memory.27−29 Shikonin and acetylshikonin,
characterized by the 5,8-dihydroxy-1,4-naphthoquinone scaf-
fold (naphthazarin), were shown to be nonselective and
reversible MAO inhibitors endowed with activity in the
micromolar range.30,31 The unsaturated and lipophilic nature
of their prenyl-like side chain resembled the hydrophobic
features of substituents decorating the present quinone-based
compounds (Figure 2), thus prompting us to also explore their
potential as MAO inhibitors.
On the whole, in terms of targets selection, we move from
amyloid and ChEs as relevant players in AD pathology to other
targets with more credentials for a disease-modifying effect,
such as tau and MAO B.32
Herein, the biological profiling included the in vitro
evaluation of (i) self-induced Aβ and tau aggregation
inhibition, (ii) the inhibitory activities against AChE and
BChE, and (iii) inhibition of MAO A and B isoforms. Atomic
force microscopy (AFM) was then employed to assess the
ability of the best performing Aβ40 inhibitors (2, 5, 11, and 12)
to impair Aβ42 fibrillation and revealed clear differences
between Aβ42 aggregate morphologies obtained in the presence
or absence of the compounds. The same compounds have
been assayed for their protective effect against Aβ42 toxicity in
primary cultures of cerebellar granule cells from postnatal rats
(P7).
2.2. Chemistry. Compounds 1, 3,33 2,34 5, 9,35 and 836
have been achieved according to the cited references. For
compound 1037 we applied a different synthetic route with
respect to the literature; thus its experimental properties have
been reported herein as follows. Naphthoquinones 4, 6, and 7
were obtained by reacting the 2,3-dichloro-1,4-naphthoqui-
none, previously suspended in ethanol or methanol, with 2
equiv of the proper amine (Schemes 1 and 2).
The condensation at 160 °C of a mixture of 1-
chloroanthraquinone with the proper aryl/heteroaryl alkyl-
amine has given compounds 10−14 (Schemes 3 and 4).
The intermediate (heteroaryl)ethylamines required for the
synthesis of the indoles 5 and 13, benzimidazole 6, and
benzotriazoles 7 and 14 were prepared by reduction with
LiAlH4 of 2-(3-indolyl)acetamide, 1-benzimidazolyl, and 1-
benzotriazolyl acetonitriles, respectively (Schemes 4 and 2).
While 2-(3-indolyl)acetamide was commercially available, to
synthesize 2-(benzimidazol-1-yl) and 2-(benzotriazol-1-yl)
acetonitriles, benzimidazole and benzotriazole were condensed
with 2-chloroacetonitrile in DMF in the presence of TEA
according to the literature.38
The structures of the novel compounds have been confirmed
using 1H and 13C NMR and elemental analysis. The purity of
compounds (checked by elemental analysis) has been in all
cases >95%.
2.3. In Silico and in Vitro Blood−Brain Barrier (BBB)
Permeation. The use of naphthoquinone and anthraquinone-
based derivatives as potential anti-AD agents requires their
ability to enter the CNS. Accordingly, we tested in silico the
propensity to cross the BBB by passive diffusion, calculating
the LogPS values39 for the new compounds in comparison to
the drugs donepezil, quercetin, safinamide, and the quinolizi-
dine-containing naphthoquinone VI (Table 1, second
column), whose BBB permeability profile was experimentally
confirmed.16
The results, listed in Table 1, predicted that all the
compounds are characterized by a brain-penetration ability
comparable to the reference compounds and sufficient to
obtain pharmacologically relevant concentrations within the
CNS. As expected, the capability of amino acids naphthoqui-
nones 8 and 9 to penetrate the BBB was poor, as LogPS values
fell close to the lower limit of the recommended ranges (−3 <
LogPS < −1), even if they could presumably reach the CNS by
carrier-mediated active transport. The in vitro permeability
(Pe) of compounds 2, 5, 8, 11, and 12 was also determined
using the PAMPA-BBB assays40 (Table 1, third column).
Successful assay validation was performed by comparing the
experimental permeability (Pe,exp) with the corresponding
reported values (Pe,rep) for 20 commercial drugs (Pe,exp =
0.9625Pe,rep + 0.2836, R
2 = 0.9622, Figure S1 and Table S1).
Scheme 1a
aReagents and conditions: (a) EtOH, Δ, 4 h.
Scheme 2a
aReagents and conditions: (a) LiAlH4 /anhydrous THF, Δ, 10 h; (b)
MeOH, rt, 24 h.
Scheme 3a
aReagents and conditions: (a) 160 °C, 6 h.
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On the basis of the Pe values obtained, all analyzed compounds
should be endowed with good-to-high BBB passive perme-
ability, with Pe values ranging from 6.1 to 28.4 × 10
−6 cm/s
(Table 1, last two columns).
2.4. Inhibition of Self-Induced Aβ Aggregation and
Cholinesterases. In vitro inhibition of Aβ40 aggregation was
assessed following a previously reported thioflavin T (ThT)
fluorescence-based method involving the use of hexafluor-
oisopropanol (HFIP) as aggregation enhancer. For the most
active compounds (≥80% Aβ aggregation inhibition) IC50
values were determined under the same assay conditions as
previously described.41 Inhibitory activities on AChE from
electric eel (eeAChE) and BChE from equine serum (esBChE)
were determined by the spectrophotometric method of
Ellman42 and are reported in Table 2 as IC50 (μM) for the
most active compounds or as percentage of inhibition at 10
μM for low active (i.e., <50%) compounds.
At a concentration of 100 μM, all the compounds 1−14
were proved to inhibit Aβ aggregation, mostly showing IC50
values in the range of 1.9−19 μM. Among them, eight (2−9)
and three (11, 12, and 14) were naphthoquinone and
anthraquinone derivatives, respectively. The compounds 1,
10, and 13 exhibited an Aβ inhibition rate of about 60% at a
concentration of 100 μM. The size of the aromatic bi- and
tricyclic system seems to influence the biological effect, as the
most potent compounds (12 and 11) sharing IC50 values equal
to 1.9 and 2.1 μM, respectively, belong to the anthraquinone
series. Previous studies have demonstrated the capability of
(hetero)aromatic tricyclic systems to establish stronger
interactions (hydrophobic and electrostatic) with the amino
acid sequence H14QKLVFF20 of Aβ, which is more prone to
aggregating.43 The length of spacer between the quinone
scaffolds and the (hetero)aromatic rings influenced the
biological activity with a different trend in the two series;
that is, one methylene unit was found as the optimal distance
for naphthoquinone-based derivatives (compare aryl deriva-
tives 2−4), while for anthraquinones the increase of the carbon
units from 1 to 3 (compare derivatives 10−12) resulted in a
proportional increase of the inhibition potency against Aβ
aggregation. Regarding the naphthoquinones linked to a
heterocyclic skeleton, the activities of the indole (5, IC50 =
6.6 μM) and benzotriazole (7, IC50 = 8.7 μM) derivatives were
comparable and about 2-fold higher than that of benzimidazole
derivative (6). Consequently, the presence of a hydrogen bond
donor group such as the NH group of indole ring rather than a
hydrogen bond acceptor feature as experienced by the N(2)
atom of the benzotriazole ring was permitted, allowing the
yield of the same degree of activity. In silico studies previously
highlighted the marginal role of NH indole in the tryptophan
derivative 9, since its N-methylation did not affect the binding
affinity to amyloid oligomers, while its NH group on
naphthoquinone C(2) and its CO group of carboxylic function
were reported as essential features for the inhibition of Aβ
aggregation.44 Our experimental data, however, pointed out
that compound 5, lacking in the COOH function, was 2-fold
Scheme 4a
aReagents and conditions: (a) LiAlH4/anhydrous THF, Δ, 8 h; (b) 160 °C, 6 h.
Table 1. In Silico and in Vitro Evaluation of
Naphthoquinone and Anthraquinone-Based Derivatives’
Propensity to Cross BBBc
aRate of brain penetration, −3 (medium affinity) < table < −1 (high
affinity). PS represents permeability−surface area product and is
derived from the kinetic equation of capillary transport. bCNS
permeation prediction based on the PAMPA-BBB classification range
from Di et al.40 cMeasured as LogPS (ACD/Percepta Platform 2015
v14.0.0, https://www.acdlabs.com/). The last two columns report the
experimental permeability results from the PAMPA-BBB assay (Pe,
10−6 cm/s) and the corresponding predictive penetration in the CNS
for compounds 2, 5, 8, 11, 12 and for donepezil and quercetin as
positive (CNS+) and negative (CNS−) controls, respectively.
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more effective than the amino acid analogue 9 such as Aβ
aggregation inhibitor. The same potencies trend was observed
for analogues 3 and 8, whereas the presence of the polar
carboxylic group in the phenylalanine derivative 8 negatively
impaired the activity. Our results corroborate the suitability of
naphthoquinone and anthraquinone scaffolds in providing Aβ
peptide inhibition, even more when properly substituted with
hydrophobic moieties able to target the aromatic interactions
occurring in the amyloid self-assembly process. Such behavior
was confirmed by AFM studies, as shown below.
By comparison of compounds 1−14 with our first series of
naphthoquinone and anthraquinones bearing a basic side chain
(Figure 1), in the case of naphthoquinones the activity
improved with 8 out of 9 compounds able to target Aβ peptide,
while the anthraquinones exhibited only a slight increase of the
potency but with a reduced number of active compounds.
Therefore, the more apolar nature of the side chain (aromatic/
heteroaromatic moiety), in place of polar basic groups,
emerged as a relevant factor in enhancing the intrinsic
capability of naphthoquinone and anthraquinone scaffolds to
target Aβ fibrillation.
Apart from the phenylamino naphthoquinone 1, all the
compounds have also been proven to inhibit AChE reaching a
low micromolar potency range. Conversely, BChE has been
found to be less sensitive to these series of compounds except
for the anthraquinone derivatives 11, 12, and 14 whose IC50
ranged from 1.7 to 8.2 μM. The most potent and selective
AChE inhibitors were the benzotriazole-based naphthoquinone
7 (IC50 = 1.7 μM) and the indole-based anthraquinone 13
(IC50 = 1.85 μM), while the anthraquinone derivatives 11 and
12 behaved as dual cholinesterase inhibitors; in particular,
compound 11 exhibited a comparable potency profile toward
the two enzymes, while 12 was 2.5-fold more selective for
BChE. In general, the new substitution pattern explored in the
present series of naphthoquinone and anthraquinone deriva-
tives on one hand positively ameliorated the inhibitory potency
against Aβ aggregation and on the other hand was responsible
for a reduced efficacy against cholinesterases, especially BChE,
in comparison to the previous series (Figure 1) which were
shown to be more potent dual inhibitors of both enzymes.16
2.5. Inhibition of hMAOs. MAO inhibition was
performed with a routine spectrophotometric assay, monitor-
ing the fluorescence of 4-hydroxyquinoline produced in the
MAO-catalyzed oxidation of kynuramine.45 With few ex-
ceptions, the title compounds acted as selective MAO B
inhibitors, thus corroborating their potential as multitarget
anti-AD agents, with IC50 values in the submicromolar range
(Table 2). It is worthy to note the high potency of N-arylalkyl
substituted naphthoquinones 2−4, whose IC50 values lay in the
nanomolar range. Benzylamine derivative 2, with IC50 equal to
7.7 nM, resulted in a potency higher than reference drug
safinamide, while 11 and 12, homologues of 3 and 4, were the
most potent MAO B inhibitors within the anthraquinone
series. Compared with phenethyl derivative 3, the substitution
of phenyl with indole (5) retained good potency, while the
introduction of different heteroaromatic systems was somehow
detrimental.
The very high potency of naphthoquinone 2 deserved
further biochemical investigation in order to clarify its
inhibition mechanism. Preliminarily we confirmed that MAO
B inhibition was not the consequence of a pan-assay
interference of 2 in the fluorimetric assay,46 by performing
the same kynuramine-based assay in spectrophotometric mode,
following the increase of absorbance of 4-hydroxyquinoline at
316 nm.47 An IC50 equal to 18 nM was obtained, in good
agreement with that reported in Table 2. Concerning the
inhibition mechanism, we detected a competitive inhibition
(inhibition constant Ki = 22 nM) when the coincubation with
enzyme was limited to 5 min (Figure S2). For higher
coincubation times (up to 2 h) the mechanism apparently
turned noncompetitive, with the Ki increasing about 20-fold.
This change could be ascribed to the formation of a covalent
complex with the N5 of flavin,48 due to the presence of the
chlorine leaving group. Indeed, a time course of absorption of
4-hydroxyquinoline at 316 nm revealed that the enzymatic
activity was still present even after 3 h in the presence of 10
nM 2 (Figure 3). This activity profile was quite comparable to
Table 2. Inhibitory Activitiesa (μM) of the Investigated Compounds 1−14 against Aβ Aggregation, ChEs, and MAOs
IC50 (μM) or (% inhibition)
b
compd Aβ40 aggr eeAChE esBChE hMAO A hMAO B
1 (63 ± 3)c (39 ± 1) (8 ± 3) (<5) (22 ± 4)
2 3.2 ± 0.8 9.2 ± 0.6 (26 ± 3) 3.6 ± 0.3 0.0077 ± 0.0013
3 4.4 ± 0.3 7.9 ± 0.8 (24 ± 1) (41 ± 3) 0.031 ± 0.001
4 8.2 ± 0.3 3.5 ± 0.3 (35 ± 3) 3.0 ± 0.2 0.054 ± 0.001
5 6.6 ± 0.1 8.7 ± 0.8 (29 ± 4) 5.0 ± 0.2 0.11 ± 0.01
6 19 ± 4 6.8 ± 0.7 (24 ± 4) (23 ± 4) (24 ± 6)
7 8.7 ± 0.4 1.7 ± 0.1 (15 ± 3) (21 ± 6) 0.48 ± 0.08
8 17 ± 2 13 ± 2 (14 ± 3) (26 ± 6) 2.7 ± 0.8
9 14 ± 2 11 ± 1 (17 ± 1) (22 ± 2) (52 ± 3)
10 (62 ± 2)c 8.7 ± 0.5 (24 ± 3) 1.1 ± 0.3 (34 ± 3)
11 2.1 ± 0.2 7.3 ± 0.7 1.7 ± 0.3 3.1 ± 0.3 0.57 ± 0.02
12 1.9 ± 0.3 7.84 ± 0.03 8.2 ± 0.4 (50 ± 3) 0.24 ± 0.05
13 (57 ± 5)c 1.85 ± 0.04 (17 ± 1) (25 ± 5) (42 ± 1)
14 11 ± 2 8.1 ± 0.5 3.4 ± 0.2 (53 ± 3) 0.98 ± 0.14
quercetin 0.82 ± 0.07
donepezil 0.021 ± 0.002 2.3 ± 0.1
safinamide (18 ± 3) 0.031 ± 0.001
aData are the mean ± SEM of n = 3 experiments. bData in parentheses correspond to % of inhibition at 10 μM, or c100 μM for inhibition of Aβ40
aggregation.
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that of 10 nM safinamide, the reference drug for reversible and
selective MAO B inhibition, when the assay was performed
without preincubation with the enzyme (Figure 3, left). With a
preincubation of 1 h, the time course of MAO B activity was
still comparable for 2 and safinamide, although 2 suffered a
strong decrease of potency (Figure 3, right). When incubated
with 100 nM pargyline, a known irreversible MAO B inhibitor,
the MAO B kinetic profiles were clearly different, since the
enzymatic activity in the presence of pargyline came to
saturation in about 1 h (Figure 3, left) and was completely
inhibited with the preincubation (Figure 3, right). We
speculate that the time-dependent change in potency of
compound 2 may be due to its inactivation, either from
chemical decomposition or from covalent reaction with
nucleophilic residues of the enzyme, rather than to the
formation of a covalent adduct with the flavin of catalytic site
of the enzyme49 and by consequence that the inhibition of 2
may be considered as reversible.
Figure 3. Time course of inhibition of MAO B by 2 (10 nM, blue line), safinamide (10 nM, red line), and pargyline (100 nM, green line): left, no
preincubation; right, 1 h preincubation with enzyme. Data points represent the absorbance of 4-hydroxyquinoline at 316 nm (n = 3; mean ± SD).
Figure 4. Details of compound 2 in the binding pocket of human MAO B (A) and human AChE (B). Compound 2 is shown as atom-colored sticks
(C, gray; O, red; N, blue; Cl, green), while the side chains of the protein residues mainly interacting with the compound are highlighted as colored
sticks and labeled. HBs/HaBs are shown as dark green broken lines, and their lengths are indicated (Å). Hydrogen atoms, water molecules, ions,
and counterions are omitted for clarity.
Figure 5. Per residue binding free energy deconvolution (PRBFED) of the enthalpic term (ΔHbind,res) for the MAO B (A) and AChE (B) residues
involved in the complex with 2. Dark-colored bars highlights those protein residues involved in stronger interactions (e.g., HBs) with the
compound in each complex.
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The results listed in Table 2 so far highlighted the
naphthoquinone 2 as the molecule endowed with the most
effective inhibitory activity against MAO B (IC50 = 7.7 nM)
and AChE (IC50 = 9.2 μM). In order to investigate the
molecular determinants for the potency and selectivity of 2
toward MAO B and AChE, molecular modeling studies were
next performed. Accordingly, the putative binding sites and
modes for 2 were first identified on both human enzymes
(Figure 4) and then molecular dynamics (MD) simulations of
the resulting inhibitor/protein complexes were carried out to
evaluate the corresponding free energy of binding (ΔGbind)
following our consolidated approach.50−56 A per-residue
binding free energy deconvolution (PRBFED) of the enthalpic
(ΔHbind,res) terms50,51 was finally performed to define and
describe the intermolecular interactions between compound 2
and the two proteins (Figure 5). The simulation results clearly
show that 2 has a substantially higher affinity for MAO B
(ΔGbind = −10.98 ± 0.16 kcal/mol) than for AChE (ΔGbind =
−7.93 ± 0.13 kcal/mol), in agreement with the relevant
experimental findings. The inspection of the relevant MD
trajectories reveals that when in complex with MAO B (Figure
4A), the two carbonyl groups of 2 are engaged in two stable
hydrogen bonds (HBs) with the monoamine oxidase side
chains of Y326 (3.21 ± 0.13 Å) (ΔHbind,res = −1.77 kcal/mol,
Figure 5A) and Y435 (2.87 ± 0.11 Å) (ΔHbind,res = −1.84 kcal/
mol, Figure 5A), respectively. Moreover, one of the −CO
groups of 2 is also permanently H-bonded with the −-NH2
moiety of MAO B Q206 (3.23 ± 0.13 Å) (ΔHbind,res = −1.21
kcal/mol, Figure 5A), while the chlorine atom of 2 interacts via
a halogen bond (HaB) with the thiol group of MAO B C172 at
an optimal distance of 2.95 ± 0.11 Å (ΔHbind,res = −1.03 kcal/
mol).57 In addition, the 2/MAO B complex is further stabilized
in the putative binding site through an extended network of
close van der Waals/hydrophobic contact interactions (CIs)
between the ligand and the side chains of MAO B residues
F103, P104, W119, L164, L167, L171, I198, I199, K296, F343,
and Y398 (∑ΔHbind,res = −4.46 kcal/mol, Figure 5A), as
highlighted in panel A of Figure 4.
On the other hand, within the putative binding site of AChE
the naphthoquinone core of 2 is involved in a π−π interaction
with AChE W286 (ΔHbind,res = −1.05 kcal/mol, Figure 5B)
and is further stabilized by weak CIs with the side chains of the
esterase residues V294, F338, and Y341 (∑ΔHbind,res = −1.36
kcal/mol, Figure 5B). One of the two −CO groups of 2
directly engages the side chain of Y72 in a long but stable HB
(3.48 ± 0.22 Å) (ΔHbind,res = −1.59 kcal/mol, Figure 5B),
while the second carbonyl moiety interacts with the −OH
group of AChE Y124 via a water-mediated HB (2.40 ± 0.33
(2···H2O), 2.38 ± 0.36 Å (Y124···H2O)) (ΔHbind,res = −1.84
kcal/mol, Figure 5A). Additionally, mildly favorable, unspecific
contacts are detected between the phenyl moiety of 2 and
AChE residues V73, T83, W86, N87, S125, and Y337
(∑ΔHbind,res = −1.69 kcal/mol, Figure 5B). Accordingly, the
interactions between 2 and AChE are definitely less optimized
than those detected in the alternative 2/MAO B complex and
provide a molecular-based rationale for the weaker (μM) and
stronger (nM) affinity of 2 for the esterase and the monoamino
oxidase, respectively.
2.6. Inhibition of PHF6 Aggregation. New evidence has
shifted our understanding about the role of tau in AD
pathogenesis, acting as crucial partner of Aβ.58 The intra-
cellular binding of soluble Aβ to nonphosphorylated tau was
detected and possibly represents a precursor event to later self-
aggregation of both molecules.59 Aβ has also been shown to
affect tau pathology through the upregulation of kinases and
proinflammatory cytokines that modulate tau phosphoryla-
tion.60 The high potency of compounds 1−14 in inhibiting Aβ
aggregation prompted us to investigate the same feature in a
smart in vitro model of tau aggregation, using as probe the
highly repeated sequence (306)VQIVYK(311) (PHF6)
responsible for aggregation of tau in paired helical fragments
(PHF).61 To this aim we developed a fast assay method based
on ThT fluorescence.45 Results in Figure 6 account for a high
potency profile of the entire set compounds in inhibiting PHF6
aggregation, with inhibition values often >90% and comparable
to reference drug quercetin. It is worthy of note that phenethyl
derivatives 3 and 11 emerged as the most potent within their
structural subsets (inhibition >95%), with IC50 values equal to
4.96 ± 0.75 μM and 1.78 ± 0.23 μM, respectively.
2.7. Inhibition of R3 Aggregation. The inhibition
exerted by 3 and 11 toward PHF6 aggregation was confirmed
in a kinetic experiment of dose-dependent aggregation of
peptide R3. The 30-amino acid peptide (V306-Q336) R3 is a
high-repeated domain containing the PHF6 sequence and
present in all tau isoforms.62 Its high propensity to self-
aggregate in buffered solutions, even in the absence of
aggregation inducers such as heparin,63 makes R3 a reliable
surrogate of full-length tau protein for in vitro experiments. In
our assay protocol, the commercial R3 peptide was pretreated
with 1,1,1-trifluoroethanol (TFE) overnight in order to
dissolve any preformed aggregate and reestablish the random
coil arrangement, then diluted in PBS at the test concentration
of 25 μM. The R3 aggregation, detected by means of ThT
fluorescence, resulted in a sigmoidal time course reaching the
plateau after 4 h of incubation at 37 °C (Figure 7). The plateau
values (as % of control) were used to derive the dose−
response curve for the calculation of IC50 values, which were
equal to 1.19 ± 0.44 μM for naphthoquinone 3 and 0.36 ±
0.02 μM for anthraquinone 11.
2.8. Inhibition of Aβ42 Fibrillation by ThT Fluores-
cence Assay. Aβ42 is the main component of circulating
amyloid peptides and majorly responsible for neurotoxicity in
AD. Its high propensity to self-aggregate allows a fast execution
of aggregation assays without the need of aggregation
enhancers as for Aβ40. The antiamyloidogenic properties of
the newly prepared compounds 1−14 were then tested also for
Aβ42 in a coincubation assay at two concentrations (100 and 5
Figure 6. Inhibition of aggregation of PHF6 tau sequence (50 μM) by
10 μM test molecules. Quercetin (QUR) was used as reference
compound. Bars represent the mean ± SD of residual aggregation
compared with control (CTR). Clear and dark filling patterns are for
naphthoquinones and anthraquinones, respectively.
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://dx.doi.org/10.1021/acschemneuro.0c00624
ACS Chem. Neurosci. 2021, 12, 447−461
453
μM) at 37 °C for 48 h. Data presented in Figure 8 confirmed
the activities already disclosed for Aβ40, with naphthoquinones
2−5 and anthraquinones 11, 12, and 14 displaying the best
activity profile. Satisfactorily, compound 2 behaved as a strong
inhibitor of Aβ42 aggregation even at the lower concentration
used, being comparable for potency to quercetin.
2.9. Inhibition of Aβ42 Fibrillation Studied by AFM.
Among the investigated compounds, the naphthoquinone
derivatives 2 and 5, and the anthraquinone derivatives 11 and
12 exhibited the highest efficiency against Aβ40 aggregation, as
demonstrated by their low IC50 values (Table 2). Moreover,
they also confirmed their antiamyloidogenic behavior against
Aβ42 peptide (Figure 8). Tapping mode atomic force
microscopy was then employed to test the ability of this
selected subset of compounds to inhibit fibrillation of the
highly amyloidogenic fragment Aβ42.
Figure 9 shows representative images of Aβ42 aggregated for
72 h in fibrillar morphology in the absence (Figure 9A) and in
the presence (Figure 9B−E) of the compounds at a molar ratio
1:2 peptide/compound. The AFM inspection allowed a
quantitative evaluation of the number of fibrils per unit area
at a fixed aggregation time in the different conditions (Figure
9F). Compared with the control, in the presence of all the
investigated compounds a significant decrease of the fibril
surface density was observed. The inhibitory effect of the
compounds was already observed after 24 h of aggregation. In
fact, although at this stage of aggregation the sample was
mainly oligomeric and the number of fibrils was low, in the
presence of the compounds there was still a decrease in the
fibrils surface density (Figure S3).
2.10. Protection against Aβ42-Induced Toxicity. The
most promising MTDLs 2, 5, 11, and 12 were also tested for
their ability to restore cell viability against the toxic effects
exerted by Aβ42. Cerebellar granule cells (CGCs) were exposed
for 48 h to 5 μM Aβ42 aggregated for 24 h with and without
the compounds (at a molar ratio peptide/compound of 1:2).
Cell viability after exposure was measured with the MTT test
(Figure 10). Compared with the control, the viability of cells
treated with Aβ42 alone decreased to 51%. In the presence of
the compounds a partial recovery of the viability was generally
observed, with compound 2 as the best neuroprotective agent.
The incomplete recovery of cell viability is probably due to
the fact that although the compounds are effective in inhibiting
aggregation of the peptide, they display some degree of toxicity
per se, as at 10 μM for any of the test compounds the cell
viability remained as high as ≥80% compared to the untreated
Figure 7. Inhibition of aggregation of R3 tau sequence (25 μM) by 11: time course of aggregation in the presence of six concentrations of 11
(ranging from 30 to 0.1 μM).
Figure 8. Inhibition of aggregation of Aβ42 (30 μM) by 100 μM (blue filling) and 5 μM (white filling) test molecules. Quercetin (QUR) was used
as reference compound. Bars represent the mean ± SD of residual aggregation compared with control. Clear and dark filling patterns are for
naphthoquinones and anthraquinones, respectively.
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control cells (Table 3). However, on the whole, the biological
results indicate for these molecules a rather narrow safety
margin (as the ratio toxicity/activity), especially considering
that most of their activities are in the micromolar range. For a
more meaningful assessment of the value of the present
compounds, the issue of their toxicity, in comparison to
established drugs for AD, should deserve further investigation.
3. CONCLUSIONS
The present work demonstrated the promiscuity profile of a
novel set of naphthoquinone and anthraquinone-based
derivatives able to tackle different factors of interest for the
efficient management of AD. These molecules were
purportedly designed to inhibit Aβ aggregation, being properly
decorated with hydrophobic moieties able to target the
aromatic interactions implicated in amyloid self-assembly. In
agreement with the design rationale the compounds signifi-
cantly inhibited Aβ40 aggregation and more interestingly the
most active derivatives (2, 5, 11, and 12) were confirmed to
disrupt fibrillation of the highly amyloidogenic fragment Aβ42.
All the compounds exhibited a preferential inhibition of AChE
than BChE and appeared to be efficient inhibitors of fast-
aggregating tau peptides PHF6 and R3. Moreover, most of
them turned out to be potent and selective MAO B inhibitors,
being able to provide IC50 values in the nanomolar or
submicromolar range with respect to the less sensitive MAO A
isoform. Outstandingly, compound 2 exhibited a remarkable
inhibitory activity against MAO B (IC50 = 7.7 nM) which was
473-fold higher than that versus MAO A. MAO enzymes
significantly contribute to the selective degeneration of
noradrenergic and cholinergic neurons in AD brains25 and
through the formation of reactive aldehydes that showed
facilitation of the conversion of β-amyloid to the hydrophobic
β-sheet conformation and subsequent fibrillogenesis in vitro.64
It is worth noting that a comparable SAR trend was observed
between the previously discussed inhibition of self-induced Aβ
aggregation and MAO, thus suggesting a potential correlation
between the two inhibition mechanisms. Finally, these MTDL
molecules were also found to ameliorate the cytotoxicity
caused by Aβ42 peptide. Collectively, these results indicate that
our series of naphthoquinone and anthraquinone derivatives
possess antiamyloidogenic properties and a multitarget profile,
thus enabling them as valuable candidates for AD therapy.
4. METHODS
4.1. Chemistry. 4.1.1. General Methods. Chemicals and solvents
were purchased from Sigma-Aldrich (Milan, Italy). Melting points
were measured using a Büchi apparatus and were uncorrected. 1H
NMR spectra and 13C NMR spectra were recorded on a Varian
Gemini-200 instrument at 200 and 50 MHz, respectively. Chemical
shifts are reported as δ (ppm) and are referenced to a solvent signal:
CDCl3, singlet at 7.26 ppm (
1H), triplet at 77.0 ppm (13C); DMSO-
d6, quintet at 2.5 ppm (
1H), septet at 39.5 ppm (13C). J is in Hz.
Elemental analyses were performed on a Flash 2000 CHNS (Thermo
Scientific) instrument in the Microanalysis Laboratory of the
Department of Pharmacy, University of Genoa. NMR spectra of the
novel compounds are shown in the Supporting Information. Results
of elemental analyses indicated that the purity of all compounds was
≥95%.
4.1.2. General Method for the Synthesis of Naphthoquinone
Derivatives (4−7). A mixture of appropriate amine (5 mmol) and 2,3-
dichloronaphthoquinone 1 (2.5 mmol) in absolute ethanol (20 mL)
was stirred under reflux for 4 h with stirring. In the case of compounds
5−7 the reaction mixture was stirred at room temperature for 24 h.
During the progress of the reaction, monitored by TLC, a change in
the color from yellow to red was observed. After evaporation of the
solvent, the residue was treated with a solution of 2 N NaOH and
CHCl3. The layers were separated, and the chloroform solution was
dried (Na2SO4), filtered, and evaporated, affording a residue that was
purified by CC (SiO2, CHCl3 + 2%MeOH).
4.1.2.1. 2-Chloro-3-(phenylpropylamino)-1,4-naphthoquinone
(4). Yield: 75%. Mp 94−96 °C. 1H NMR (200 MHz, CDCl3) δ:
8.40−8.00 (m, 2H, arom); 7.84−7.58 (m, 2H, arom); 7.41−7.18 (m,
5H, arom); 6.15 (s, 1H, NH); 3.90 (q, J = 7 Hz, 2H,
NHCH2CH2CH2Ar); 2.77 (t, J = 7.6 Hz, 2H, NHCH2CH2CH2Ar);
2.07 (quint, J = 6.8 Hz, 2H, NHCH2CH2CH2Ar).
13C NMR (50
MHz, CDCl3) δ: 179.4, 175.8, 143.0, 139.7, 133.9, 131.7, 131.4,
128.6, 127.5, 127.3, 125.8, 125.2, 43.2, 31.8, 31.5. Anal. Calcd for
C19H16ClNO2: C 70.05; H 4.95; N 4.30. Found: C 70.30; H 5.17; N
4.17.
4.1.2.2. 2-[2-(1H-Benzimidazol-1-yl)ethylamino]-3-chloro-1,4-
naphthoquinone (6). Yield: 49%. Mp 205−207 °C. 1H NMR (200
MHz, CDCl3) δ: 8.22 (s, 1H, arom); 7.88 (s, 1H, arom); 7.58−7.18
(m, 4H, arom); 6.98−6.77 (m, 1H arom); 6.76−6.42 (m, 2H, arom);
6.24 (broad s, 1H, NH); 3.70−3.40 (m, 2H, NHCH2CH2-
N(1)Benz); 3.34−2.98 (m, 2H, NHCH2CH2-(N1)Benz). 13C NMR
(50 MHz, CDCl3) δ: 172.9, 153.6, 142.7, 140.0, 137.6, 131.4, 129.6,
Figure 9. Inhibition of Aβ42 fibrillation tested by AFM. Tapping mode
AFM images of Aβ42 after 72 h of aggregation at room temperature in
the absence (A) and in the presence of compounds 2 (B), 5 (C), 11
(D), and 12 (E). Scan size was 5.0 μM. Z range was 25 nm. (F)
Quantitative evaluation of the fibril surface density (number of fibrils
per unit area) in the absence and in the presence of the compounds.
Mean values obtained on at least six different areas of 100 μm2 are
reported. Errors were calculated using Student’s statistics, assuming a
confidence level of 95%.
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128.5, 124.5, 124.0, 121.9, 118.5, 112.0, 105.6, 48.5, 44.9. Anal. Calcd
for C19H14ClN3O2: C 64.87; H 4.01; N 11.94. Found: C 64.63; H
4.28; N 12.06.
4.1.2.3. 2-{[2-(1H-Benzotriazol-1-yl)ethy]amino}-3-chloro-1,4-
naphthoquinone (7). Yield: 39%. Mp 193−194 °C. 1H NMR (200
MHz, DMSO) δ: 8.05−7.65 (m, 5H, arom); 7.62−7.41 (m, 2H,
arom); 7.39−7.23 (m, 1H, arom); 6.29 (s, 1H, NH); 4.98 (t, J = 5.8
Hz, 2H, NHCH2CH2-N(1)Bzt); 4.24 (q, J = 6.2 Hz, 2H,
NHCH2CH2-N(1)Bzt).
13C NMR (50 MHz, DMSO) δ: 179.6,
174.9, 145.2, 144.7, 134.4, 134.2, 132.7, 132.3, 131.1, 129.6, 126.8,
126.0, 125.3, 123.5, 118.6, 110.1, 47.8, 43.0. Anal. Calcd for
C18H13ClN4O2: C 61.28; H 3.71; N 15.88. Found: C 61.17; H
3.77; N 15.98.
4.1.3. General Method for the Synthesis of Anthraquinone
Derivatives (10−14). A mixture of 1-chloroanthraquinone (2.5
mmol) with the suitable amino compound (2.5 mmol) was heated
at 160 °C in a sealed tube for 6 h. After cooling, the mixture was
treated with 2 M NaOH until alkalinity and extracted with CHCl3.
After removal of the solvent, the residue was purified by CC (SiO2/
CHCl3 + 2% MeOH).
4.1.3.1. 1-(Benzylamino)-9,10-anthraquinone (10). Yield: 90%.
Mp 171−173 °C. 1H NMR (200 MHz, CDCl3) δ: 8.43−8.19 (m, 2H,
arom); 7.96−7.61 (m, 4H, arom); 7.60−7.20 (m, 6H, arom); 7.17−
6.98 (m, 1H, NH); 4.62 (s, 2H, NHCH2Ar).
13C NMR (50 MHz,
CDCl3) δ: 184.2, 182.7, 150.4, 136.9, 136.7, 134.3, 133.9, 133.6,
133.5, 132.9, 132.6, 132.0, 127.8, 126.5, 126.4, 126.0, 125.7, 117.3,
115.1,112.4, 46.0. Anal. Calcd for C21H15NO2: C 80.49; H 4.82; N
4.47. Found: C 80.11; H 5.20; N 4.17.
4.1.3.2. 1-(Phenethylamino)-9,10-anthraquinone (11). Yield:
71%. Mp 100−103 °C. 1H NMR (200 MHz, CDCl3) δ: 8.42−8.20
(m, 2H, arom); 7.90−7.70 (m, 2H, arom); 7.68−7.51 (m, 3H, arom);
7.48−7.22 (m, 5H, arom); 7.11 (dd, 1H, J = 1.6, 6.6 Hz, NH); 3.63
(t, J = 7.2 Hz, 2H, NHCH2CH2Ar); 3.10 (t, J = 7.8 Hz, 2H,
NHCH2CH2Ar).
13C NMR (50 MHz, CDCl3) δ: 184.0, 182.8, 150.4,
137.7, 134.3, 134.0, 133.7, 131.9, 127.7, 126.5, 125.7, 116.7, 114.7,
112.1, 43.6, 34.6. Anal. Calcd for C22H17NO2: C 80.71; H 5.23; N
4.28. Found: C 80.62; H 5.04; N 3.98.
4.1.3.3. 1-[(3-Phenylpropryl)amino]-9,10-anthraquinone (12).
Yield: 76%. Mp 115−116 °C. 1H NMR (200 MHz, CDCl3) δ:
8.42−8.21 (m, 2H, arom); 7.90−7.70 (m, 2H, arom); 7.68−7.48 (m,
2H, arom); 7.42−7.18 (m, 6H, arom); 7.06 (dd, 1H, J = 1.6, 8.2 Hz,
NH); 3.38 (t, J = 7.0 Hz, 2H, NHCH2CH2CH2Ar); 2.86 (t, J = 7.4
Hz, 2H, NHCH2CH2CH2Ar); 2.15 (quint, J = 7.2 Hz, 2H,
NHCH2CH2CH2Ar).
13C NMR (50 MHz, CDCl3) δ: 183.9, 182.8,
150.6, 140.1, 134.2, 133.9, 133.5, 132.9, 131.9, 128.3, 127.5, 127.4,
125.7, 125.6, 125.1, 116.8, 114.6, 111.8, 41.0, 32.1, 29.5. Anal. Calcd
for C23H19NO2: C 80.92; H 5.61; N 4.10. Found: C 80.73; H 5.98; N
3.93.
4.1.3.4. 1-{[2-(1H-Indol-3-yl)ethyl]amino}-9,10-anthraquinone
(13). Yield: 40%. Mp 240−241 °C. 1H NMR (200 MHz, CDCl3)
δ: 10.84 (s, 1H, NH of indole); 8.18−7.41 (m, 7H, arom); 7.39−6.82
(m, 5H, arom); 6.60 (s, 1H, NH); 3.98 (pseudo s, 2H,
NHCH2CH2Ind); 2.99 (pseudo s, 2H, NHCH2CH2Ind).
13C NMR
(50 MHz, CDCl3) δ: 184.6, 182.6, 150.0, 135.8, 134.4, 134.2, 132.1,
131.5, 130.5, 129.5, 126.6, 126.0, 125.3, 122.7, 120.6, 117.9, 110.9,
110.3, 44.2, 33.0. Anal. Calcd for C24H18N2O2: C 78.67; H 4.95; N
7.65. Found: C 78.81; H 4.95; N 7.43.
4.1.3.5. 1-{[2-(1H-Benzotriazol-1-yl)ethyl]amino}-9,10-anthra-
quinone (14). Yield: 42%. Mp 176−177 °C. 1H NMR (200 MHz,
CDCl3) δ: 8.36−8.15 (m, 3H, arom); 7.86−7.57 (m, 5H, arom);
7.55−7.22 (m, 3H, arom); 6.82 (s, 1H, NH); 4.57 (t, J = 7.0 Hz, 2H,
NHCH2CH2-N(1)Bzt); 3.03 (t, J = 7.0 Hz, 2H, NHCH2CH2-
N(1)Bzt). 13C NMR (50 MHz, CDCl3) δ: 184.5, 183.7, 146.2, 144.0,
135.9, 133.9, 133.4, 132.9, 132.0, 127.8, 126.9, 125.8, 125.0, 121.9,
119.0, 48.5, 44.2. Anal. Calcd for C22H16N4O2: C 71.73; H 4.38; N
15.21. Found: C 71.59; H 4.31; N 15.20.
4.1.4. General Method for the Synthesis of Intermediates:
Tryptamine, 2-(Benzimidazol-1-yl)ethylamine, and 2-(Benzotria-
zol-1-yl)ethylamine. To a suspension of LiAlH4 (40 mmol) in 20 mL
of anhydrous THF cooled at 0−5 °C, a solution of 3-indolylacetamide
or 2-(benzimidazol-1-yl)acetonitrile or 2-(benzotriazol-1-yl)-
acetonitrile (10 mmol) in anhydrous THF (5 mL) was added drop
by drop in 20 min. Then the mixture was refluxed for 8−10 h. At rt 5
Figure 10. Protection against Aβ42 toxicity in cerebellar granule cells. The CGCs were treated with vehicle (control) or with Aβ42, with or without
the tested compounds, for 48 h. Cell viability was measured by MTT reduction test and expressed as loss of viability in comparison with vehicle-
treated controls. Values have been obtained from at least three experiments. Compound + Aβ vs Aβ: *p < 0.01, **p < 0.02, ***p < 0.05.
Table 3. In Vitro Cytotoxicity of Compounds 2, 5, 11, 12a
compound 2 5 11 12
cell viability vs control
(%)
89 ± 14 85 ± 14 85 ± 15 77 ± 12
aThe CGCs were treated with the compounds (10 μM) for 48 h. Cell
viability was measured by MTT reduction test and expressed as loss of
viability in comparison with vehicle-treated controls. Values have been
obtained from at least three experiments. Data are expressed as the
mean ± SEM.
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mL of H2O, 5 mL of 2N NaOH, and 5 mL of H2O were carefully
added to the mixture to decompose the excess of LiAlH4, filtering and
washing the inorganic residue with Et2O. The solution was dried with
Na2SO4, filtered, and evaporated to dryness, yielding an orange oil
corresponding to the title ethylamino derivative that was chromato-
graphed on SiO2 eluting with Et2O.
These intermediates were already prepared through different
procedures; thus they were characterized as follows.
4.1.4.1. Tryptamine. Yield: 81%. 1H NMR (200 MHz, CDCl3) δ:
10.11 (s, NH of indole), 7.71−7.52 (m, 2H, arom), 7.39−7.20 (m,
2H, arom), 7.16−7.03 (m, 1H, arom), 4.88 (broad s, NH2), 3.09−
2.95 (m, 4H, CH2CH2-NH2). Anal. Calcd for C10H12N2: C 74.97; H
7.55; N 17.48. Found: C 74.81; H 7.95; N 17.23.
4.1.4.2. 2-(Benzimidazol-1-yl)ethylamine. Yield: 76%. 1H NMR
(200 MHz, CDCl3) δ: 8.21 (s, 1H, arom), 7.65−7.49 (m, 2H, arom),
7.35−7.21 (m, 2H, arom), 4.97 (broad s, NH2), 4.19−4.01 (m, 2H,
N-CH2), 3.16−3.07 (m, 2H, CH2-NH2). Anal. Calcd for C9H11N3: C
67.06; H 6.88; N 26.07. Found: C 66.91; H 6.79; N 26.31.
4.1.4.3. 2-(Benzotriazol-1-yl)ethylamine. Yield: 76%. 1H NMR
(200 MHz, CDCl3) δ: 8.11−7.71 (m, 2H, arom), 7.52−7.31 (m, 2H,
arom), 5.01 (broad s, NH2), 4.22 (pseudo s, 2H, N-CH2), 3.45
(pseudo s, 2H, CH2-NH2). Anal. Calcd for C8H10N4: C 59.24; H
6.21; N 34.54. Found: C 59.01; H 6.56; N 34.16.
4.2. Biological Tests. 4.2.1. Inhibition of Self-Induced Aβ
Aggregation. Aβ40 and Aβ42 peptides were purchased from EzBiolab,
Carmel, IN, USA. In vitro inhibition assay of Aβ40 aggregation has
been previously reported41 and adapted to a 96-well plate platform.
Briefly, samples of Aβ40 (30 μM) were coincubated for 2 h at 25 °C
with test molecules (100 μM for single point concentration assay,
seven concentrations ranging from 100 to 0.1 μM for IC50
calculations) in PBS containing 2% v/v of HFIP.
Inhibition of Aβ42 aggregation was assayed by incubating the
peptide (30 μM) alone (as the control) or with test compounds (5 or
100 μM) in PBS at 37 °C for 48 h.
After incubation in 96-well black, nonbinding microplates (Greiner
Bio-One GmbH, Frickenhausen, Germany), thioflavin T (25 μM) was
added and fluorimetric reads (ex 440, em 485 nm) were performed in
a multiplate reader Infinite M1000 Pro (Tecan, Cernusco sul
Naviglio, Italy). Experiments were run in triplicate. Results were
expressed by statistical analysis while IC50 values were obtained by
nonlinear regression using Prism software (GraphPad Prism version
5.00 for Windows, GraphPad Software, San Diego, CA, USA).
4.2.2. Inhibition of Cholinesterases. The classical Ellman’s
method, modified to a 96-well plate platform, was used as already
described.65 AChE from electric eel (463 U/mL), BChE from horse
serum (13 U/mL), acetyl- and butyrylthiocholine, and dithiobis(2-
nitrobenzoic acid) were purchased from Sigma-Aldrich, Milan, Italy.
Experiments were run in triplicate, and inhibition values were
obtained by nonlinear regression using Prism software.
4.2.3. Inhibition of Human Monoamine Oxidases. The
fluorimetric assays of MAO A and B following the oxidation of
kynuramine to 4-hydroxyquinoline (ex 310, em 400 nm in NaOH)
were performed as described.45 All enzymes and reagents were
purchased from Sigma-Aldrich. For inhibition kinetics, four
concentrations of 2 (ranging from 0 to 20 nM) and five
concentrations of kynuramine (from 2 to 30 μM) were used. Direct
spectrophotometric measurement of 4-hydroxyquinoline absorption
at 316 nm was performed as described.47 Inhibition values and kinetic
parameters were calculated by means of Prism.
4.2.4. Inhibition of PHF6 Aggregation. The fluorimetric assay,
using thioflavin T as the chromophoric reagent, has already been
described.45 Briefly, samples of PHF6 (JPT Peptide Technologies
GmbH, Berlin, Germany) (50 μM), inhibitor (10 μM), and ThT (10
μM) were prepared in triplicate in PBS containing 3.3% of 1,1,1-
trifluoroethanol and read within 3 h at 30 °C with a Tecan Infinite
M1000 Pro instrument. The plateau values (as % of residual activity
compared to control) were used for the calculation of residual
aggregation or in nonlinear regression by means of Prism to calculate
the IC50 values as the mean of two independent experiments.
4.2.5. Inhibition of R3 Aggregation. A stock solution of 1.5 mM
R3 (trifluoroacetate salt; Bachem, Bubendorf, Switzerland) was
prepared in TFE and left overnight at room temperature. Incubation
samples were set in nonbinding, flat-bottomed black microplates
(Greiner Bio-One) in triplicate for each concentration and contained
peptide (25 μM), inhibitor (seven concentrations ranging from 30 to
0.1 μM), and ThT (10 μM) in PBS containing 1.7% of 1,1,1-
trifluoroethanol. Fluorescence was read within 4 h at 37 °C with a
Tecan Infinite M1000 Pro instrument. IC50 values were calculated by
means of Prism as the mean of two independent experiments.
4.2.6. Atomic Force Microscopy. Compounds 2, 5, 11, and 12
were dissolved in DMSO at concentrations ranging from 2.0 mg/mL
to 3.3 mg/mL. Aβ42 (Bachem) was dissolved in TFA to obtain a 1
mg/mL stock solution. In each experiment, appropriate peptide
aliquots were deposited in glass vials and dried under a gentle
nitrogen stream. Aggregation was initiated by hydrating the peptide
with PBS premixed with the compound under study. The final
compound and peptide concentrations were 100 μM and 50 μM,
respectively. In the control samples, PBS was premixed with DMSO
volumes equivalent to those present in the compound aliquots
employed for the experiments. Aggregation was performed at room
temperature.
For AFM inspection, sample aliquots of 20 μL were deposited on a
freshly cleaved mica surface and incubated for 7 min. Samples were
then gently rinsed with Milli-Q water and dried overnight under mild
vacuum. Tapping mode AFM images were acquired in air using a
Dimension 3100 SPM (Bruker, Karlsruhe, Germany) equipped with
“G” scanning head (maximum scan size 100 μm) and driven by a
Nanoscope IIIa controller (Bruker). Single-beam uncoated silicon
cantilevers (type TESPA_V2, Bruker) were used. The drive frequency
was 300−320 kHz, and the scan rate was 0.5 Hz.
4.2.7. Primary Cultures. Cerebellar granule cells were prepared
from 8-day-old Sprague Dawley rats as described previously.66 Cells
were studied from the 6th to the 12th day in vitro. The experimental
procedures and care of the animals were performed in compliance
with the Directive of the EU Parliament and Council of September
22, 2010 (2010/63/EU) and were approved by the Italian Ministry of
Health (COD. 75F11.N.6DX) in accordance with D.M. 116/1992.
All efforts were made in order to minimize animal suffering and the
number of animals necessary to obtain reliable results.
4.2.8. Cell Survival Assay. Cerebellar granule cells in 48-well plate
were treated with Aβ42, aggregated in PBS for 24 h, in the absence and
in the presence of each tested compound in the same conditions
described in section 4.2.6. The final compound and Aβ42
concentrations after addition to the well plate were 10 μM and 5
μM, respectively. Cells were maintained in 5% CO2 at 37 °C. The cell
viability was assessed by the MTT assay 48 h after the treatment.
MTT [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide] (Sigma-Aldrich, Germany) was added to the medium at a
concentration of 0.25 mg/mL (MTT) into each well, and the
multiwell plates were incubated for 3 h at 37 °C. After the removal of
the medium, formazan crystals were dissolved in DMSO and the
values of optical density (OD) were measured spectrophotometrically
at 570 nm using a BioTek ELx800 (Winooski, VT, USA) microplate
reader. The survival rates of viable cells were calculated by comparing
the optical absorbance of treated samples with that of the untreated
controls. All experiments were repeated at least three times
independently, and data are expressed as the mean ± SEM.
4.2.9. In Vitro Blood−Brain Barrier Permeation Assay (PAMPA-
BBB). Prediction of the brain permeation of compounds 2, 5, 8, 11,
and 12 was evaluated using a parallel artificial membrane permeation
assay (PAMPA-BBB), following a well-established procedure.40,50
Briefly, a semiautomated pipetting system (BenchSmart 96, Mettler
Toledo) and a microplate spectrophotometer (SpectraMax Plus 384
microplate reader, Molecular Devices) were employed for pipetting
and UV reading, respectively. All commercial drugs and reagents were
purchased from Sigma-Aldrich. The porcine brain lipid (PBL) was
acquired from Avanti Polar Lipids, while Millex filter units (PVDF
membrane, pore size 0.45 μm) were obtained from Millipore. For the
assay, the 96-well acceptor microplate (PTFE, Millipore) was filled
ACS Chemical Neuroscience pubs.acs.org/chemneuro Research Article
https://dx.doi.org/10.1021/acschemneuro.0c00624
ACS Chem. Neurosci. 2021, 12, 447−461
457
with 300 μL of PBS:ethanol (70:30), whereas the artificial membrane
of the donor microplate (PVDF membrane, pore size 0.45 μm,
Millipore) was coated with 4 or 5 μL of PBL dissolved in dodecane
(20 mg/L). All compounds were first dissolved in DMSO and then
diluted with PBS/EtOH (70:30, pH 7.4) to reach the final
concentration in the range 40−100 μM in the donor well, filtered
through a Millex filter, and then added to the donor microplate wells
(200 μL). The donor filter microplate was carefully placed onto the
acceptor microplate so as to form a sandwich, which was left
undisturbed for 16 h at 25 °C into a sealed container with wet paper
towels to avoid evaporation. After incubation, the donor microplate
was cautiously removed and the concentrations of the tested
compounds in the acceptor and donor microplate wells were
determined via UV−vis spectroscopy. Every sample was analyzed at
five wavelengths in four wells and in three independent runs.
Accordingly, the results given in Table 1 are reported as average
values ± standard deviation. Pe was calculated by the following
formula: Pe = {−VdVa/[(Vd + Va)At]} × ln(1 − drugacceptor/
drugequilibrium), where Vd and Va are the volumes of the donor and
acceptor wells, respectively, A is artificial membrane area, t is the
permeation time, drugacceptor is the absorbance obtained in the
acceptor well, and drugequilibrium is the theoretical equilibrium
absorbance. Twenty known commercial drugs of known BBB
permeability (Table S1, Figure S1) were used as quality control
standards to validate and normalize the analysis set. Donepezil and
quercetin were further tested as CNS+ and CNS− positive and
negative controls, respectively (Table 1). Upon completion of the
PAMPA-BBB assay for each present and standard compound, lipid
membrane integrity was verified based on the transport of Lucifer
Yellow (Sigma-Aldrich), a fluorescent molecule with very poor
membrane permeability which, in the presence of a uniform and
integral lipid membrane, should effectively be completely rejected.67
The Lucifer Yellow test was performed following Millipore protocol
lit. no. PC1545EN00 (https://www.sigmaaldrich.com/technical-
documents/protocols/biology/membrane-integrity-test-for-lipid-
pampa-artificial-membranes.html). As the relevant fluorescence read-
ings (SpectraMax Gemini XPS microplate reader, Molecular Devices)
were comparable to background readings of buffer only (5% DMSO
in PBS), the membrane integrity after all PAMPA-BBB assays was
confirmed.
4.3. Molecular Modeling Studies. All simulations were carried
our using Amber 2068 running on our own CPU/GPU cluster.
Molecular graphics and analyses were performed with UCSF Chimera
(v1.15),69 developed by the Resource for Biocomputing, Visual-
ization, and Informatics at the University of California, San Francisco,
with support from NIH Grant P41-GM103311. The starting
molecular structure of MAO B in complex with E98 was obtained
from the Protein Data Bank (PDB code 6FWC.pdb),70 while the
AChE structure in complex with a flavonoid-based inhibitor was taken
from our previous work50,51 (original PBD code 4EY7).71 The entire
modeling and simulation procedure is also reported in detail in earlier
papers.50,51 Briefly, the geometry- and energy-optimized structure of
compound 2 was docked into each identified protein binding pocket
using Autodock 4.2.6/Autodock Tools1.4.616172 on a win64
platform. The resulting complexes were further energy minimized to
convergence. Each intermolecular complex was then solvated by a
cubic box of TIP3P water molecules73 and energy minimized using a
combination of molecular dynamics (MD) techniques.50,51 20 ns
molecular dynamics (MD) simulations at 298 K were then employed
for system equilibration, and further, 50 ns MD simulations were run
for data production. The binding free energies of the 2/MAO B and
2/AChE complexes were calculated following the MM/PBSA
methodology74 as previously described.50−56 The PRBFED analysis
was carried out using the molecular mechanics/generalized
Boltzmann surface area (MM/GBSA) approach,75 as already
detailed,50,51 and was based on the same snapshots used in the
binding free energy calculation.
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